PET Imaging of 68Ga-Her2-affibody in Tumors With High Her2 Expression - Trial NCT06289517
Access comprehensive clinical trial information for NCT06289517 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Not yet recruiting. The study focuses on Neoplasms. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University First Hospital
Timeline & Enrollment
N/A
Apr 01, 2024
Jun 30, 2025
Primary Outcome
The diagnostic efficacy of 68Ga-Her2-affibody PET/CT in the evaluation of breast cancer
Summary
This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic
 efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status
 of HER2, aiming to provide a new imaging method for the determination of HER2 status in
 breast cancer At the same time, it also provides new methods and means for early diagnosis,
 accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of
 malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and
 provides scientific basis for precise treatment of malignant tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06289517
Non-Device Trial